Table 3. Number of children with virological failure^* over time.

	Month 6	Month 12	p-values**	Odds Ratio(95%%CI)
Parent status
Both died	12(38)	6(21)	0.872	0.9(0.4–2.0)
At least one lives	34(39)	11(15)
Caregiver's educational status
Completed at least Primary school	17(37)	9(19)	0.678	0.6(0.3–3.1)
Non educated	30(39)	16(20)
Distance from healthcare center
Living in Kigali	22(40)	9(17)	0.567	0.8(0.5–2.7)
Outside of Kigali	28(41)	13(19)
Age group
Age ≥5 years at cART initiation	21(29)	7(11)	0.006	2.6(1.3–5.2)
Age <5 years at cART initiation	25(52)	10(25)
Immunological status at baseline
CD4≥15% or 350/mm3	21(34)	6(12)	0.282	1.5(0.7–2.9)
CD4<15% or <350/mm3	23(43)	10(20)
WHO stage at baseline
Baseline WHO I&II	8(35)	0	0.171	1.7(0.8–3.9)
Baseline WHO III&IV	37(39)	16(19)
95% Adherence
Adherent	26(32)	12(15)	0.009	2.5(1.3–5.0)
Non-adherent	20(53)	5(24)
PMTCT exposure
No-exposure	26(31)	9(12)	0.003	3.4(1.5–7.9)
Exposure	14(58)	6(38)
Regimen switch up to 6 or 9 months
No treatment change	40(37)	12(14)	0.337	1.6(0.6–4.3)
Treatment change	6(54)	7(49)

*Virological failure defined as VL≥1000 copies/mL for one measurement;

**between group comparisons.

P values bold: significant difference at p<0.05.